Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.

Antimicrobial agents and chemotherapy - 1 Aug 2014

Ricardo Elisabete, Miranda Isabel M, Faria-Ramos Isabel, Silva Raquel M, Rodrigues Acácio Gonçalves, Pina-Vaz Cidália

Abstract excerpt

Candida krusei is an important agent of opportunistic infections that often displays resistance to several antifungals. We describe here the in vivo acquisition of resistance to voriconazole (VRC) by C. krusei isolates recovered from a leukemia patient during a long period of VRC therapy. In order to mimic the in vivo development of VRC resistance, a susceptible C. krusei isolate was exposed daily to 1 μg/ml of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Candida
Share to Candidiasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Fungal

Share to Fluconazole

Share to Opportunistic Infections

Share to Sterol 14-Demethylase

Share to Tacrolimus

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 24867987
DOI: 10.1128/AAC.02603-14
PMCID: PMC4136031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.PMID 24867987Read ↗

ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei.Semantic proximity Read ↗

Dynamics of in vitro development of azole resistance in Candida tropicalisSemantic proximity Read ↗

Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.Semantic proximity Read ↗

Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.Semantic proximity Read ↗

Overexpression of efflux pump transporter genes and mutations in ERG11 pave the way to fluconazole resistance in Candida tropicalis: A study from a North India region.Semantic proximity Read ↗

Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.Semantic proximity Read ↗

In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment.Semantic proximity Read ↗

Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida kruseiSemantic proximity Read ↗

MDR1 overexpression combined with ERG11 mutations induce high-level fluconazole resistance in Candida tropicalis clinical isolates.Semantic proximity Read ↗

The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans.Semantic proximity Read ↗

Detection of ERG11 Overexpression in Candida albicans isolates from environmental sources and clinical isolates treated with inhibitory and subinhibitory concentrations of fluconazole.Semantic proximity Read ↗

Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.